APOE and risk of cognitive impairment in multiple sclerosis

Acta Neurol Scand. 1999 Nov;100(5):290-5. doi: 10.1111/j.1600-0404.1999.tb00398.x.

Abstract

Objectives: The APOE gene polymorphism and the -491 A/T polymorphism in its regulatory region have been associated with an increased risk for developing Alzheimer's disease. We examined these polymorphisms in multiple sclerosis (MS) patients, to determine if a genetic predisposition may explain the risk for developing cognitive decline in MS.

Material and methods: Eighty-nine relapsing-remitting and secondary progressive MS patients underwent to a full neuropsychological battery as well as to determination of APOE and -491 A/T polymorphisms. Genetic analysis was also performed in 107 population controls.

Results: The APOE polymorphism was not associated with the risk of cognitive impairment in MS patients. The AA genotype of the -491 A/T polymorphism in the APOE regulatory region was more frequent in cognitively impaired than in cognitively preserved MS subjects.

Conclusion: The AA homozygous state of the -491 A/T polymorphism of the APOE regulatory region is associated with cognitive impairment in patients with MS.

MeSH terms

  • Adult
  • Amino Acid Sequence
  • Apolipoproteins E / genetics*
  • Cognition Disorders / etiology*
  • Cognition Disorders / genetics
  • Female
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Molecular Sequence Data
  • Multiple Sclerosis / complications
  • Multiple Sclerosis / genetics*
  • Multiple Sclerosis / psychology
  • Polymorphism, Genetic*
  • Risk Assessment

Substances

  • Apolipoproteins E